|ATC code||G04BE11 (WHO)|
|Biological half-life||7.3–12.1 hours|
|Chemical and physical data|
|Molar mass||516.657 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
The drug udenafil, marketed under the trade name Zydena, is within the PDE5-inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Used, like other PDE5 inhibitors, to treat erectile dysfunction, undenafil was developed by Dong-A Pharmaceutical. With action of fairly rapid onset (peak plasma concentration after 1 to 1.5 hours) yet long duration (plasma half life of 11 to 13 hours), udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use). Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines; in the United States, it has not been approved by the U.S. Food and Drug Administration.
- Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.
- "Udenafil: Efficacy and tolerability in the management of erectile dysfunction".
- [http://www.drugs.com/international/zydena.html "Zydena", Drugs.com